Navigation Links
Novelos Therapeutics and MUSC Present Two Posters at AACR 2007,Annual Meeting

for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit www.novelos.com

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

Contact

Novelos Therapeutics, Inc.
Harry S. Palmin, 617-244-1616 x11
President and CEO
hpalmin@novelos.com
or
Investor Relations:
Stephen Lichaw, 201-240-3200
slichaw@novelos.com


'"/>




Page: 1 2

Related medicine technology :

1. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:5/4/2015)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) has entered ... to develop and commercialize ISIS-FXI Rx for the ... Isis is eligible to receive up to $155 million ... payment and a $55 million payment upon advancement of ... with compromised kidney function. Isis is also eligible to ...
(Date:5/4/2015)... May 4, 2015 Unchained Labs, a refreshingly ... this year,s PEGS conference and launches the UNit — ... biologics. PEGS: The Essential Protein Engineering Summit takes place ... The UNit lets drug discovery researchers look ... out there. Its 7 applications, 144 sample a day ...
(Date:5/4/2015)... Fla. , May 4, 2015 ... biotechnology company whose patented and proprietary technologies are ... other proteins for the bioenergy, bio-based chemical, biopharmaceutical ... will report its financial results for quarter ending ... May 14, 2015 and will host a conference ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5Unchained Labs Lets the UNit Loose 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
... Much of Sultan Kosen,s eight feet, two-inch stature rose ... the benign tumor in his brain,s pituitary gland ... growth hormone, making Mr. Kosen,s body grow fast and grow ... find out if his Gamma Knife ® surgery last ...
... Aug. 26 Alexza Pharmaceuticals, Inc. (Nasdaq: ... Staccato nicotine technology to Cypress Bioscience, Inc. ... a novel electronic multidose delivery system designed to help ... is intended to improve on a well-validated smoking cessation ...
Cached Medicine Technology:World's Tallest Man Stretches Out—Over Eight Feet—for Needed Gamma Knife Surgery 2World's Tallest Man Stretches Out—Over Eight Feet—for Needed Gamma Knife Surgery 3World's Tallest Man Stretches Out—Over Eight Feet—for Needed Gamma Knife Surgery 4Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 2Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 3Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 4
(Date:5/4/2015)... The University of California, Davis ... new initiative at UC Davis School of Medicine ... committed to advancing Latino health. , The program, ... Students to Be Physicians, (“Prep Médico” for short) ... mentorship and internship opportunities, a residential program, intensive ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Each year, the ... to raise funds and awareness for breast cancer. This year, ... will be featured as the entertainment sponsor for the 25th ... on May 9 at the Lenox Square Mall. , The ... race, and to raise $1.2 million. Perimeter Plastic Surgery has ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a groundbreaking ceremony ... on Wednesday, April 22. , Johnson & Wales becomes the ... the re-alignment of Interstate-195. JWU’s new academic building, which will ... in Providence, is scheduled to be completed in July 2016. ... university purchased in 2012. , “It has long been our ...
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
(Date:5/4/2015)... 2015 Baptist Medical Center Jacksonville ... Get With The Guidelines®-Stroke Gold Plus Quality Achievement ... The award recognizes the hospital’s commitment and success ... appropriate treatment according to nationally recognized, research-based guidelines ... receive the Gold Plus Quality Achievement Award, hospitals ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4
... drugs to fix what healthy living would cure, researcher says, ... eating right, exercising and keeping your weight down are well-known, ... , In fact, over the past two decades exercise rates ... in the meantime obesity rates have soared, a new study ...
... TORONTO, Ont., May 28, 2009 When Chicago Blackhawk,s ... game four of the Western Conference Final after sustaining ... surrounding his swift return. According to a new study ... questions were raised by 25% of minor league hockey ...
... leaders for vision, determination and drive to address today,s ... , a part of Experian and a leader ... that its president, Daniel Johnson, has been named as ... the Year(R) Award in Minnesota and the Dakotas."I am ...
... the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish ... been made by the responsible Grants Committee of the ... centres will initially be funded for four years with ... this, the DFG will also provide 20 percent overhead ...
... launches campaign for stricter regulatory approval requirements and continuity of product ... ... 2009 -- A recent report released by Wolters Kluwer Health predicts ... drug prescriptions will be filled with generic drugs. This march ...
... HEIGHTS, Ohio, May 27 Allscripts announced today ... Allscripts Professional(R) Electronic Health Record ... multi-specialty practices across suburban Cleveland, Ohio. (Logo: ... hospital and health center with its own physician ...
Cached Medicine News:Health News:Americans Score Low on Healthy Lifestyle 2Health News:Americans Score Low on Healthy Lifestyle 3Health News:Minor league hockey players unable to identify concussion symptoms, study says 2Health News:Minor league hockey players unable to identify concussion symptoms, study says 3Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 2Health News:SearchAmerica(R) President Named as a Finalist for the Ernst & Young Entrepreneur of the Year(R) Award 3Health News:DFG establishes nine new collaborative research centers 2Health News:DFG establishes nine new collaborative research centers 3Health News:DFG establishes nine new collaborative research centers 4Health News:DFG establishes nine new collaborative research centers 5Health News:DFG establishes nine new collaborative research centers 6Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 2Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 3Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 4Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 5Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 2Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 3Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 4Health News:Southwest General Health Center Selects Allscripts Web-Hosted Electronic Health Record 5
... Chart Manager information can be input ... are not limited to drop-down lists ... each person to document individually. Patient ... valuable data and communication. All this ...
AllMeds was the first specialty-specific Electronic Medical Record for Orthopaedics. Instead of trying to force a general-purpose EMR into your practice, AllMeds starts with clinical content from Ort...
... software It runs over hospital ... PAS systems and some items ... collects data at initial consultation, ... checks, operation, post-op checks, telephone ...
... such as prescription writing, referral letters, chart ... will be ,able to add more appointments ... staff., Based on the exam documentation created ... recommend the appropriate E&M ,code for the ...
Medicine Products: